Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2011.37.0312 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Buerger's rabbit model: a closer step to unravelling thromboangiitis obliterans?
Thromb J
July 2024
Department of Vascular Surgery, Fudan University Pudong Medical Center, Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai, 201399, China.
Objective: Thromboangiitis obliterans (TAO) remains clinical challenging due to its rarity and underwhelming management outcomes. This study aimed to describe a novel TAO rabbit model that demonstrates a closer resemblance to TAO.
Methods: Thirty-six New Zealand rabbits underwent the surgical implantation of calibrated gelatin sponge particles (CGSPs) into their right femoral artery.
Prognostic Value of CSF IL-10 at Early Assessment of Induction Chemotherapy in Primary CNS Lymphomas: A LOC Network Study.
Neurology
June 2024
From the Departments of Neurooncology (D.H., A.L., A.A., K.H.-X., C.H.), Biological Hematology (M.L.G.-T., E.S.), Clinical Hematology (S.C., I.B.), Neuro-radiology (L.N.), Neurosurgery (B.M.), and Neuropathology (K.M.), Hôpital Pitié-Salpêtrière, Paris; and Clinical Hematology (C.S., M.A.) Institut Curie, Saint Cloud, France.
Objectives: Despite a high response rate at the first evaluation during induction chemotherapy, the risk of early relapse remains high and unpredictable in primary CNS lymphomas (PCSNLs). We aimed to assess the prognostic value of early IL-10 levels in CSF (e-IL-10) after 2 months of induction chemotherapy.
Methods: We retrospectively selected from the LOC (Lymphomes Oculo-Cérébraux) network database patients with PCSNLs who had complete or partial response at the 2-month evaluation of a high-dose methotrexate-based first-line chemotherapy for whom e-IL-10 was available.
Predicting treatment response to methotrexate: are we closer to solving the enigma?
Rheumatology (Oxford)
May 2024
Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Erythrodermic Presentation of Atopic Dermatitis in a Patient with Secondary Adrenal Insufficiency Caused by Oral Glucocorticosteroid Abuse.
Acta Dermatovenerol Croat
November 2023
Alicja Mesjasz, Dermatological Students Scientific Association, Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of GdanskFaculty of Medicine, Medical University of Gdansk, Gdansk 80-214, Gdansk, Poland;
Dear Editor, A 41-year-old man presented to the Department of Dermatology for the first time due to an exacerbation of atopic dermatitis (AD) in the form of erythroderma. The patient had a history of atopic diseases, with being AD active from infancy. On clinical examination, generalized erythematous skin lesions causing acute pruritus and accompanied by severe skin exfoliation and dryness were present.
View Article and Find Full Text PDFThe treatment of chronic refractory moderate-to-severe atopic dermatitis (AD) has traditionally relied on broad-spectrum systemic anti-inflammatory agents. With the introduction of biologics and Janus kinase inhibitors (Jakinib), the step management of moderate-to-severe AD is rapidly changing; however, guidelines have yet to provide formal recommendations for how to best incorporate these agents into the treatment plan. To summarize the updated evidence-based medical treatment for AD, including a proposed position for biologics and Jakinibs in the treatment algorithm.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!